<?xml version="1.0" encoding="UTF-8"?>
<p>Since SARS-CoV-2 is a newly discovered pathogen, no specific drugs have been identified or are currently available. An economic and efficient therapeutic strategy is to repurpose existing drugs. On the basis of genomic sequence information coupled with protein structure modeling, the scientific community has been able to rapidly respond with a suggested list of existing drugs with therapeutic potential for COVID-19. 
 <xref rid="tbl4" ref-type="other">Table 
  <xref rid="tbl4" ref-type="other">4</xref>
 </xref> provides a summary of such drugs together with potential mechanisms of actions for their activities. Barcitinib was proposed because of its anti-inflammatory effect and possible ability to reduce viral entry.
 <sup>
  <xref ref-type="bibr" rid="ref35">35</xref>
 </sup> A fixed dose of the anti-HIV combination, lopinavirâ€“ritonavir, is currently in clinical trials with Arbidol or ribavirin.
 <sup>
  <xref ref-type="bibr" rid="ref22">22</xref>
 </sup> Remdesivir, developed by Gilead Sciences Inc., was previously tested in humans with Ebola virus disease and has shown promise in animal models for MERS and SARS. 
 <ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/news-events/remdesivir-prevents-mers-coronavirus-disease-monkeys" xmlns:xlink="http://www.w3.org/1999/xlink">The drug is currently being studied in phase III clinical trials in both China and the USA</ext-link>. Favipiravir, a purine nucleoside leading to inaccurate viral RNA synthesis,
 <sup>
  <xref ref-type="bibr" rid="ref36">36</xref>
 </sup> was originally developed by Toyama Chemical of Japan, and has recently been approved for a clinical trial as a drug to treat COVID-19.
 <sup>
  <xref ref-type="bibr" rid="ref30">30</xref>
 </sup> Chloroquine, an antimalarial drug, has proven effective in treating coronavirus in China.
 <sup>
  <xref ref-type="bibr" rid="ref32">32</xref>
 </sup> In addition to the above-mentioned, many other antiviral drugs are also listed.
</p>
